"AIDS Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
| Descriptor ID |
D016915
|
| MeSH Number(s) |
D20.215.894.899.050
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "AIDS Vaccines".
Below are MeSH descriptors whose meaning is more specific than "AIDS Vaccines".
This graph shows the total number of publications written about "AIDS Vaccines" by people in this website by year, and whether "AIDS Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 2 | 0 | 2 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "AIDS Vaccines" by people in Profiles.
-
Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. PLoS Pathog. 2018 02; 14(2):e1006888.
-
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2014 Jul 01; 210(1):99-110.
-
Procedures for mucosal immunization and analyses of cellular immune response to candidate HIV vaccines in murine and nonhuman primate models. Methods Mol Biol. 2014; 1184:417-55.
-
Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. PLoS Pathog. 2011 Feb; 7(2):e1002002.
-
Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality. PLoS One. 2010 Dec 22; 5(12):e14385.
-
Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. Expert Rev Vaccines. 2010 Jun; 9(6):645-64.
-
Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine. 2010 Jul 12; 28(31):5114-27.
-
Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA). World J Surg. 2009 Apr; 33(4):653-60.
-
Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One. 2009; 4(3):e5059.
-
Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine. 2009 May 26; 27(25-26):3335-41.